ArticleIrish journal of medical science2026
Dose-related effects of dexmedetomidine on wound healing: evaluating fibroblast activation, collagen synthesis, and prolidase activity.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDexmedetomidine (Dex) is known for extending the time of action and enhancing the analgesic efficacy of local anesthetics. However, its effects on surgical wound healing have not been comprehensively investigated.
aimThis study aims to thoroughly examine the effects of subcutaneously administered Dex on wound healing in rats.
methods32 rats in total were randomly distributed into four groups: Control, 3 ml Saline (Group I), 5 μg/kg Dex (Group II), 30 μg/kg Dex (Group III), and 60 μg/kg Dex (Group IV). After the procedure, samples were collected from the surgical wound site on the 7th day. Several wound-healing-related parameters were measured, including arginase, collagen type I, hydroxyproline, Xaa-Pro dipeptidase/prolidase, transforming growth factor-β (TGF-β1), and basic fibroblast growth factor (bFGF). Additionally, the immunoreactivity of proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor (VEGF) proteins was assessed to evaluate connective tissue cell proliferation and blood vessel development in the dermis.
resultsHydroxyproline (ng/ml) levels were significantly higher in Groups II, III, and IV compared to Group I. Statistically significant differences were also observed between the groups for Arginase (ng/ml), Collagen Type I (ng/ml), TGF-β1 (ng/L), and bFGF (ng/L) values. PCNA immunoreactivity was significantly higher in the 30 μg/kg group than in other groups. VEGF immunoreactivity was significantly higher in the 5 μg/kg group.
conclusionThe subcutaneous administration of Dex did not negatively impact wound healing in rats. Histological and biochemical findings showed that doses of 5 and 30 μg/kg promoted the fastest wound closure and supported homogeneous tissue formation. These results suggest that dexmedetomidine has therapeutic potential in wound healing.
Indexed as
Identifiers
41452557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.